WebIn 2015, we initiated a phase 3 open-label randomised controlled trial, the IFCT-GFPC-0701 Mesothelioma Avastin plus Pemetrexed-cisplatin Study (MAPS), which showed an overall survival benefit when adding bevacizumab to standard cisplatin plus pemetrexed chemotherapy (median overall survival 18·8 months [95% CI 15·9–22·6] with … Web1 Department Of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), 1011 - Lausanne/CH; 2 Thoracic Oncology Unit, Hopital Arnaud de Villeneuve, Montpellier/FR; 3 Frontier Science Foundation-hellas, National and Kapodistrian University of Athens, Athens/GR; 4 Iis-fjd, Hospital Universitario Fundacion Jimenez Díaz, Madrid/ES; 5 …
Nivolumab or nivolumab plus ipilimumab in patients with …
Web19 mrt. 2024 · Systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 14 days before initiation of the immunotherapy … WebThe primary objectives are: - To evaluate the effect of steady-state simeprevir and daclatasvir on the steady-state pharmacokinetics of cyclosporine and tacrolimus when administered as a regimen containing simeprevir (150 mg qd), daclatasvir (60 mg qd) and RBV (1000 to 1200 mg per day) in post-OLT subjects with recurrent HCV genotype 1b … armadi 53
No Benefit for Post-operative Radiotherapy in Non-small-cell Lung …
WebDICIPLE (IFCT-1701) Appareil pulmonaire. Essai clinique fermé. Public cible. Adulte. A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab … WebBackground: There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control has been less than 30% in all previous studies of second-line drugs. Preliminary results have suggested that anti-programmed cell death 1 (PD-1) monoclonal antibody could be … WebBR.31 (IFCT1401) Appareil pulmonaire. Essai clinique fermé. Public cible. Adulte. A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant … balonmano bera bera